- Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
- Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
- Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
More ▼
Key statistics
On Friday, Kezar Life Sciences Inc (KZR:NSQ) closed at 0.705, 4.51% above its 52-week low of 0.6746, set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.731 |
---|---|
High | 0.744 |
Low | 0.703 |
Bid | 0.701 |
Offer | 0.744 |
Previous close | 0.7286 |
Average volume | 658.59k |
---|---|
Shares outstanding | 72.80m |
Free float | 62.00m |
P/E (TTM) | -- |
Market cap | 53.04m USD |
EPS (TTM) | -1.40 USD |
Data delayed at least 15 minutes, as of May 24 2024 21:00 BST.
More ▼